Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease

NCT06295679 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06295679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06295679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease
Lead sponsor
Amgen
Phase
Observational
Overall status
Active, not recruiting
Start date
December 19, 2022
Completion date
December 19, 2028
Enrollment
7,000 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

established atherosclerotic cardiovascular disease, major cardiovascular event